Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients With B-Cell Acute Lymphoblastic Leukemia With an Option of Extended Use of Forodesine Hydrochloride

NCT00289562 is registered in ClinicalTrials.gov with BioCryst Pharmaceuticals as lead sponsor.

NCT NCT00289562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00289562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients With B-Cell Acute Lymphoblastic Leukemia With an Option of Extended Use of Forodesine Hydrochloride
Lead sponsor
BioCryst Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2004
Completion date
December 31, 2007
Enrollment
20
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia